Venezuela's PDVSA to produce, refine and export crude previously handled by Chevron, document says
Trump nominates Republic Airways CEO Bryan Bedford as US FAA head
Trading Day: Global rebound enters day two, Wall St lags
Iran tells UN: Trump's remarks are 'reckless and provocative'
Canada's Carney says Trump must stop comments before bilateral talks can start
China's Xi may visit US in not-too-distant future, Trump says
Coco Gauff heads home to the Miami Open after her 21st birthday and a bit of a rough patch
Some of the WNBA's rising stars have shined during Unrivaled's inaugural season
Shohei Ohtani merchandise is prompting long lines -- even in the rain -- in Tokyo
(Reuters) - The U.S. Centers for Disease Control and Prevention said on Wednesday it expects to see an increase in levels of COVID-19 and respiratory syncytial virus (RSV) in the country in the coming weeks, as they usually do during the holiday season.
Large gatherings, travel and more time indoors, which typically happen during the holiday season, tend to cause more viruses to spread easily, the health agency said.
CDC expects hospitalizations for flu and COVID-19 to start increasing in the coming weeks. It also sees increased RSV activity, particularly in young children, in the southern and eastern U.S.
The U.S. Food and Drug Administration had approved updated COVID-19 vaccines made by Pfizer and its German partner BioNTech, as well as Moderna in August. The health regulator also granted emergency use authorization for Novavax's traditional protein-based shot.
Currently, there are three FDA-approved RSV vaccines made by GSK, Moderna and Pfizer.
As of Oct. 5, 11.2% of adults aged 18 years or above received an updated COVID-19 vaccine and 36.9% of adults 75 years or older received an RSV shot, according to CDC data.
(Reporting by Christy Santhosh in Bengaluru; Editing by Shilpi Majumdar)
